Bibliography
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344 , 1383–1389 (1994).
- Baigent C , BlackwellL, EmbersonJ et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.Lancet376 , 1670–1681 (2010).
- Armitage J , BowmanL, WallendszusK et al.: Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.Lancet376 , 1658–1669 (2010).
- Law M , RudnickaAR: Statin safety: a systematic review.Am. J. Cardiol.97 , 52C–60C (2006).
- Mangravite LM , KraussRM: Pharmacogenomics of statin response.Curr. Opin. Lipidol.18 , 409–414 (2007).
- Niemi M : Role of OATP transporters in the disposition of drugs.Pharmacogenomics8 , 787–802 (2007).
- Tokui T , NakaiD, NakagomiR, YawoH, AbeT, SugiyamaY: Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, OATP2.Pharm. Res.16 , 904–908 (1999).
- Cui Y , KonigJ, LeierI, BuchholzU, KepplerD: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6.J. Biol. Chem.276 , 9626–9630 (2001).
- Tirona RG , LeakeBF, MerinoG, KimRB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European– and African–Americans.J. Biol. Chem.276 , 35669–35675 (2001).
- Romaine SP , BaileyKM, HallAS, BalmforthAJ: The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.Pharmacogenomics J.10 , 1–11 (2010).
- Couvert P , GiralP, DejagerS et al.: Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.Pharmacogenomics9 , 1217–1227 (2008).
- Takane H , MiyataM, BuriokaN et al.: Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy.J. Hum. Genet.51 , 822–826 (2006).
- Link E , ParishS, ArmitageJ et al.: SLCO1B1 variants and statin-induced myopathy – a genomewide study.N. Engl. J. Med.359 , 789–799 (2008).
- Voora D , ShahSH, SpasojevicI et al.: The SLCO1B1*5 genetic variant is associated with statin-induced side effects.J. Am. Coll. Cardiol.54 , 1609–1616 (2009).
- Pirruccello J , KathiresanS: Genetics of lipid disorders.Curr. Opin. Cardiol.25(3) , 238–242 (2010).